Merck & Co., Inc. $MRK Holdings Boosted by Osprey Private Wealth LLC

Osprey Private Wealth LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 15.7% in the first quarter, HoldingsChannel reports. The firm owned 33,820 shares of the company’s stock after purchasing an additional 4,580 shares during the quarter. Osprey Private Wealth LLC’s holdings in Merck & Co., Inc. were worth $4,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter worth $31,000. Finally, High Note Wealth LLC raised its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday. Morgan Stanley upped their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.72.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock traded down $1.35 during mid-day trading on Friday, reaching $123.72. The company had a trading volume of 8,388,403 shares, compared to its average volume of 10,797,806. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $130.29. The company has a 50 day moving average of $118.83 and a 200-day moving average of $116.28. The firm has a market cap of $305.56 billion, a price-to-earnings ratio of 34.85, a PEG ratio of 2.68 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.